Results 231 to 240 of about 495,708 (385)
Arthritis &Rheumatology, Accepted Article.Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro +17 more
wiley +1 more source
A systematic qualitative review of ethical issues in open label placebo in published research. [PDF]
Sci RepRichard M, Bernstein M, Gaab J, Elger B.
europepmc +1 more source
Teaching neurons to respond to placebos
Journal of Physiology, 2016 F. Benedetti +7 more
semanticscholar +1 more source
Arthritis &Rheumatology, Accepted Article.Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli +4 more
wiley +1 more source
Deceptive Caffeine Shows Limited Impact on Short-Term Neuromuscular Performance. [PDF]
NutrientsValero F +4 more
europepmc +1 more source
THE EFFECTIVENESS OF RENALOF® COMPARED TO KALKURENAL® AND PLACEBO
, 2012 Benny Kristyantoro +3 more
openalex +1 more source
Arthritis &Rheumatology, Accepted Article.Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes in youth with axial juvenile spondyloarthritis (axJSpA) initiating TNF inhibitor (TNFi).
Timothy G. Brandon +8 more
wiley +1 more source
Problematic placebos in physical therapy trials.
Journal of Evaluation In Clinical Practice, 2016 M. Maddocks +3 more
semanticscholar +1 more source